DCRI Think Tank Suggests Approach for Incorporating Patient-Reported Outcome Measures into Clinical Trials
A “validity argument” approach takes into account that the context of each trial is different and attempts to overcome barriers historically associated with measuring and reporting patient-reported
ABC Science Collaborative Finds Schools Are Safe, Even During COVID-19 Winter Surge; Transmission is Higher for Extracurricular Events Such as Sports
Despite a surge in community cases in winter 2020, within-school transmission remained low, with most transmission within high schools occurring in school-sponsored sports. New data analyzed and published by the DCRI-led ABC Science Collaborative sheds new light on school safety during a COVID-19 surge and reinforces the message that masking is an effective strategy to mitigate within-school transmission.
Increasing Health Care System Participation in Research Requires New Support Systems
DCRI Executive Director Adrian Hernandez, MD, MHS, and co-authors recently published a commentary in the New England Journal of Medicine advocating for new ways to incentivize health care systems t
Report Shows that N.C. K-12 Schools Reopened Safely, Paving the Way for Schools Nationwide to Limit COVID-19 Spread in the Classroom
Top scientists and physicians from the ABC Science Collaborative have shared insights from North Carolina schools, coupled with a science-based blueprint for all schools to resume full, in-person instruction safely. A new report issued today by the DCRI-led ABC Science Collaborative shows that North Carolina schools were highly successful in preventing the transmission of COVID-19 within school buildings and offers science-based learnings for the nation’s schools to limit COVID-19 spread.
DCRI and HumanFirst Collaborate to Improve Scientific Rigor for Digital Measures
The Duke Clinical Research Institute (DCRI) and HumanFirst announced today the creation of a new Digital Measures Evaluation Center for assessing sensors and other digital measures used in clinical research. HumanFirst, previously known as Elektra Labs, is a technology company leading the development of digital platforms to evaluate and enable the deployment of connected technologies in decentralized trials and virtual care.
Randomized, Pragmatic Trial Testing Antimicrobial Therapy for Treatment of Idiopathic Pulmonary Fibrosis Shows No Significant Effect
A large pragmatic study in idiopathic pulmonary fibrosis (IPF) found that antimicrobial therapy did not have a statistically significant effect on respiratory hospitalization or death compared with usual care alone.
What ADAPTABLE Has Taught Us
Following the presentation of results from DCRI’s ADAPTABLE
ACC 2021: CONNECT-HF Provides New Data on Heart Failure Quality Improvement
The late-breaking clinical trial found no difference between the intervention group and the control group when examining an audit and feedback initiative that was hypothesized to improve heart failure care. An effort to improve the quality of heart failure care focused on audit and feedback did not significantly improve either the outcomes of patients with heart failure or the quality of care they received, according to late-breaking clinical trial results presented today at the American College of Cardiology’s 70th annual Scientific Session & Expo.
ACC 2021: ACTION Trial Shows Oral Anticoagulation with Rivaroxaban Does Not Help Patients With COVID-19
Late-breaking clinical trial results provide new insight into how to treat patients who are hospitalized with COVID-19 and at risk for blood clots. Findings from the ACTION trial, which was led by the Brazilian Clinical Research Institute in collaboration with DCRI’s Renato Lopes, MD, PhD, were presented by Lopes Sunday at the American College of Cardiology’s 70th annual Scientific Session & Expo. Results were also published after the conference in The Lancet.
ACC 2021: ADAPTABLE Answers the Aspirin Question, Provides Framework for Novel Research Methods
Results from a landmark clinical trial that sought to determine the safest and most effective dose of aspirin for patients with existing cardiovascular disease were presented Saturday morning as part of the 70th annual American College of Cardiology Scientific Session & Expo.